Rep. April McClain Delaney Sells Bio-Techne Corp (NASDAQ:TECH) Shares

Representative April McClain Delaney (Democratic-Maryland) recently sold shares of Bio-Techne Corp (NASDAQ:TECH). In a filing disclosed on March 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Bio-Techne stock on February 24th.

Representative April McClain Delaney also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of EMCOR Group (NYSE:EME) on 2/27/2026.
• Sold $1,001 – $15,000 in shares of Jones Lang LaSalle (NYSE:JLL) on 2/27/2026.
• Purchased $1,001 – $15,000 in shares of Nasdaq (NASDAQ:NDAQ) on 2/27/2026.
• Sold $1,001 – $15,000 in shares of Morningstar (NASDAQ:MORN) on 2/25/2026.
• Sold $1,001 – $15,000 in shares of Fortune Brands Innovations (NYSE:FBIN) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Jones Lang LaSalle (NYSE:JLL) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of CDW (NASDAQ:CDW) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Paychex (NASDAQ:PAYX) on 2/23/2026.
• Purchased $15,001 – $50,000 in shares of Clean Harbors (NYSE:CLH) on 2/23/2026.

Bio-Techne Stock Performance

Shares of TECH stock opened at $53.62 on Thursday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.08 and a current ratio of 4.54. The firm has a market cap of $8.39 billion, a P/E ratio of 105.14, a P/E/G ratio of 3.51 and a beta of 1.48. The firm’s 50 day moving average price is $62.56 and its 200-day moving average price is $59.99. Bio-Techne Corp has a one year low of $46.01 and a one year high of $72.16.

Bio-Techne (NASDAQ:TECH) last announced its earnings results on Wednesday, February 4th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.03. Bio-Techne had a return on equity of 13.94% and a net margin of 6.67%.The company had revenue of $295.88 million for the quarter, compared to analyst estimates of $290.20 million. During the same quarter in the previous year, the company earned $0.42 earnings per share. The firm’s quarterly revenue was down .4% compared to the same quarter last year. As a group, equities research analysts predict that Bio-Techne Corp will post 1.67 EPS for the current year.

Bio-Techne Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, February 27th. Stockholders of record on Monday, February 16th were paid a $0.08 dividend. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, February 13th. Bio-Techne’s payout ratio is 62.75%.

Analyst Ratings Changes

Several equities research analysts recently issued reports on TECH shares. Zacks Research upgraded Bio-Techne from a “strong sell” rating to a “hold” rating in a report on Monday, February 9th. Stifel Nicolaus set a $65.00 target price on Bio-Techne and gave the company a “hold” rating in a report on Thursday, February 5th. Benchmark reaffirmed a “buy” rating on shares of Bio-Techne in a research report on Tuesday, February 3rd. Evercore boosted their price target on shares of Bio-Techne from $62.00 to $68.00 and gave the stock an “in-line” rating in a research note on Thursday, February 5th. Finally, Wells Fargo & Company increased their price target on shares of Bio-Techne from $70.00 to $76.00 and gave the stock an “overweight” rating in a research report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $72.77.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Blue Trust Inc. boosted its stake in shares of Bio-Techne by 109.7% in the 3rd quarter. Blue Trust Inc. now owns 453 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 237 shares during the period. Danske Bank A S purchased a new stake in shares of Bio-Techne during the fourth quarter worth approximately $29,000. eCIO Inc. purchased a new stake in shares of Bio-Techne during the fourth quarter worth approximately $30,000. Allworth Financial LP raised its holdings in Bio-Techne by 68.1% in the second quarter. Allworth Financial LP now owns 612 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 248 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC purchased a new position in Bio-Techne in the third quarter worth approximately $32,000. 98.95% of the stock is owned by institutional investors and hedge funds.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Bio-Techne Company Profile

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.